News from mitsubishi tanabe pharma america, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 13, 2022, 08:04 ET Mitsubishi Tanabe Pharma America Announces FDA Approval of RADICAVA ORS® (edaravone) for the Treatment of ALS

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the U.S. Food and Drug Administration (FDA) has approved RADICAVA ORS® (edaravone), the ...

Apr 28, 2022, 09:00 ET Target ALS and Mitsubishi Tanabe Pharma America Announce Winner of the First Annual Rebecca Luker Courage Award

Target ALS today announced Merit E. Cudkowicz, Chief of the Neurology Department at Massachusetts General Hospital, as the winner of the first annual ...

Apr 04, 2022, 09:00 ET Mitsubishi Tanabe Pharma America Presents Real-World Data on RADICAVA® (edaravone) at 2022 American Academy of Neurology Annual Meeting

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of an analysis of real-world data that suggest continued treatment of...

Apr 01, 2022, 09:00 ET Mitsubishi Tanabe Pharma America to Showcase ALS Research at 2022 American Academy of Neurology Annual Meeting

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four presentations on amyotrophic lateral sclerosis (ALS) will be shared as part of the ...

Mar 11, 2022, 09:00 ET Mitsubishi Tanabe Pharma America Highlights ALS Research at 2022 MDA Clinical & Scientific Conference

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that five presentations on amyotrophic lateral sclerosis (ALS) will be shared as part...

Jan 12, 2022, 09:00 ET Mitsubishi Tanabe Pharma America Announces FDA Acceptance of New Drug Application (NDA) for Oral Edaravone Formulation for the Treatment of ALS

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) ...

Dec 10, 2021, 09:00 ET Mitsubishi Tanabe Pharma America Presents REFINE-ALS Biomarker Study Details at Virtual 32nd International Symposium on ALS/MND

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced virtual poster presentations reviewing the Phase 4 REFINE-ALS biomarker study in people ...

Dec 09, 2021, 09:00 ET Mitsubishi Tanabe Pharma America Announces Results from the Global Phase 3 Safety Study of Investigational Oral Edaravone in the Treatment of ALS

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced 24-week results from the global Phase 3 open-label study evaluating the safety and...

Dec 01, 2021, 09:00 ET Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Research at Virtual 32nd International Symposium on ALS/MND

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations on amyotrophic lateral sclerosis (ALS) as part of the Motor Neurone ...

Oct 15, 2021, 09:00 ET Mitsubishi Tanabe Pharma America Announces Presentations at 146th Annual Meeting of the American Neurological Association

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that two abstracts on amyotrophic lateral sclerosis (ALS) will be presented during the...

Oct 06, 2021, 09:00 ET Mitsubishi Tanabe Pharma America Highlights ALS Research at Northeast Amyotrophic Lateral Sclerosis 20th Annual Meeting

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that five presentations on amyotrophic lateral sclerosis (ALS) will be shared as part...

Aug 09, 2021, 09:00 ET Mitsubishi Tanabe Pharma America Celebrates Fourth Anniversary of U.S. Availability of RADICAVA® (edaravone) for Treatment of ALS

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that nearly 6,000 people with amyotrophic lateral sclerosis (ALS) in the U.S. have...

Jul 27, 2021, 09:00 ET Mitsubishi Tanabe Pharma America and Target ALS Announce Call for Nominations for First Annual Rebecca Luker Courage Award

Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Target ALS today announced the establishment of the inaugural Target ALS Rebecca Luker Courage...

Jun 30, 2021, 09:00 ET Mitsubishi Tanabe Pharma America Announces EXSERVAN™ (riluzole) is Now Available in the U.S. for the Treatment of ALS

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that EXSERVAN™ (riluzole), the first oral film formulation of riluzole, is now...

Jun 25, 2021, 09:00 ET MTPA Announces PANTHERx® Selected as Exclusive Provider of U.S. Specialty Pharmacy Services for EXSERVAN™ (riluzole) Oral Film

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced PANTHERx Rare Pharmacy has been selected as the exclusive provider of specialty...

May 12, 2021, 15:10 ET Mitsubishi Tanabe Pharma America to Present Analysis of Real-World Claims Data for Patients Treated With RADICAVA® (edaravone) During 2021 European Network to Cure ALS (ENCALS) Virtual Meeting

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it will present findings from a new analysis of claims data from a cohort of patients...

Apr 20, 2021, 09:00 ET Mitsubishi Tanabe Pharma America Presents Analysis Examining Real-World Data on ALS Patient Disease Progression Milestones

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of an analysis of the timing of disease progression milestones among...

Mar 18, 2021, 09:12 ET Post-Hoc Analysis of Phase 3 Study Examines Effect of Early Intervention with Edaravone on Survival and Disease Progression Milestone Events in ALS Patients

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous ...

Mar 17, 2021, 10:30 ET Mitsubishi Tanabe Pharma America Presents Data on Impact of ALS Symptoms on Patients' Ability to Independently Conduct Daily Activities

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from a new analysis evaluating the impact of symptom progression on the...

Mar 03, 2021, 13:00 ET Mitsubishi Tanabe Pharma America Announces Establishment of NeuroDiscovery Lab Research Base in Cambridge, Mass.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Mitsubishi Tanabe Pharma Holdings America, Inc. (MTHA) plans to establish a new...

Feb 08, 2021, 09:12 ET Mitsubishi Tanabe Pharma America Celebrates Five Years of Dedication to the ALS Community in the U.S.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today celebrated its five-year anniversary of being established in the United States in 2016. MTPA has...

Jan 21, 2021, 08:30 ET Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment

Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced a licensing and supply deal for the U.S....

Jan 14, 2021, 09:00 ET Mitsubishi Tanabe Pharma America Announces Enhancements to Out-Of-Pocket Assistance Program for Eligible ALS Patients Treated with RADICAVA® (edaravone)

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced upgrades to its out-of-pocket assistance program that aim to provide enhanced support...

Jan 07, 2021, 09:00 ET Mitsubishi Tanabe Pharma America Revises REFINE-ALS Biomarker Study Process to Enable Remote Participation

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced revisions to the REFINE-ALS biomarker study protocol to address the safety of people...

Dec 22, 2020, 09:00 ET Mitsubishi Tanabe Pharma America Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase ...